Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Adlyxine | lixisenatide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Juxtapid | Lomitapide | Hypercholesterolemia, homozygous familial | Do not list | Complete | ||
| Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Complete | ||
| Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete | ||
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older | Do not reimburse | Complete | ||
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation | Do not reimburse | Complete | ||
| Oxlumo | lumasiran | Primary hyperoxaluria type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete |
Last Updated : May 17, 2024